A Novel Generative AI-Designed T-Cell Receptor Bispecific for Cancer Immunotherapy
Time: 3:40 pm
day: Conference Day Two
Details:
- Application of the proprietary machine learning platform, EMLyTM , for TCR discovery leading to the generation of a lead PRAME TCR
- TCR engineering using EMLyTM for rapid affinity enhancement of the parent molecule by more than 5 million-fold
- Development of a functional TCR bispecific from this lead molecule, and current advancement towards preclinical phase
